Which is NOT one of the adverse effects associated with second generation antipsychotics (SGAs)?

Neuroleptic Malignant Syndrome (NMS) is a rare but serious condition that can occur with antipsychotic medications, particularly the first-generation (typical) antipsychotics. While second-generation antipsychotics do have their own set of adverse effects, NMS is not typically associated with them in the same way it is with first-generation agents.

In contrast, weight gain, the development of Type 2 Diabetes Mellitus (DM II), and hyperglycemia are well-documented adverse effects of second-generation antipsychotics. These medications can lead to significant metabolic changes, which include insulin resistance and dysregulation of glucose metabolism, contributing to the risk of developing diabetes and resulting in weight gain. Common examples of second-generation antipsychotics that may lead to these issues include clozapine and olanzapine.

Understanding the distinction in side effect profiles between first and second-generation antipsychotics is crucial in psychiatric practice, particularly when considering the long-term management of patients and the potential for adverse metabolic effects with SGAs.